What Lacrinorm Treats: Main Uses and Benefits

Ocular lubricants such as Lacrinorm are commonly used in the symptomatic management of dry eye conditions. Such products are often included in self-care approaches.

Soothing Ocular Discomfort Symptoms

Lacrinorm is commonly used to help manage symptoms related to physical discomfort, and is relevant for easing sensations of dryness, grittiness, and eye irritation. It is applied in scenarios where additional management of discomfort is required, and may assist with symptomatic support that helps patients cope more steadily with these irritative manifestations.

Supporting Functional Ocular Stability

This gel is relevant for easing symptoms linked to functional stress of the eye. It assists with maintaining functional stability, which contributes to improved day-to-day comfort during symptomatic periods. This is applicable in contexts that involve acute or disruptive symptom patterns and in conditions involving episodic or fluctuating manifestations.

Quick Fact: Applied for Dryness and Irritation

Regulatory References

1. NHS Guidance on Ocular Lubricants for Dry Eyes

Eligibility Map: Who can and cannot use Lacrinorm — Official Regulatory Information

The eligibility profile for Lacrinorm (Carbomer Ophthalmic Gel) is determined by the official population-based rules set forth in regulatory documents.

Connection to the Overall Eligibility Profile

Official regulatory documents define non-eligibility primarily through a single absolute contraindication—hypersensitivity to the product's ingredients. All other population rules define eligibility by established experience (children and the elderly), a precautionary restriction (pregnancy and lactation) due to insufficient data, or a mandatory constraint for contact lens wearers.

Interactions with other medicines and products

Lacrinorm (Carbomer ophthalmic gel) is primarily a locally acting tear substitute, and regulatory documentation confirms that the high molecular weight of the active ingredient results in negligible systemic absorption.

Systemic Drug Interactions

Due to the lack of systemic exposure, Lacrinorm is not associated with classic systemic drug interactions. No clinically relevant interactions with oral or systemic medications, food, alcohol, or herbal products are documented in official prescribing information, as metabolic and transporter-mediated interactions are considered non-applicable.

Local Ocular and Device Interactions

Interactions are constrained to the ocular surface and involve co-administered topical products and medical devices. This profile is defined by two constraints:

These timing and sequencing rules are mandated to manage the gel’s pharmacodynamic effect, which can prolong the ocular contact time of co-administered topical medicines.

Lacrinorm is formulated as an ophthalmic gel, leveraging the high molecular weight polymer, Carbomer 980 (polyacrylic acid), as its principal active constituent. Upon topical application to the ocular surface, the polyacrylic acid component targets the corneal and conjunctival epithelial surface. The polymeric chains, which contain numerous carboxyl groups, interact with the aqueous phase of the tear film and ocular surface mucus layer. This interaction involves a physical process of hydration and swelling, significantly increasing the formulation's viscosity. The increase in viscosity is a direct rheological consequence of the polymer's cross-linked structure expanding as it absorbs water. This physical modification results in the polymer forming a non-specific, high-residence time gel network that adheres to the epithelial cells. This sustained adhesion modulates the systemic physiological parameter of tear film clearance rate, physically prolonging the retention of the aqueous vehicle on the eye's surface. A secondary component, benzalkonium chloride, exhibits broad-spectrum membrane disruption activity via interaction with microbial cell walls, resulting in a non-specific antimicrobial effect.

How Lacrinorm is Used

Lacrinorm (Carbomer ophthalmic gel) is administered exclusively via the ocular route, meaning it is instilled directly onto the eye surface. Standard guidelines define the precise manner in which the medicine is to be used, focusing on correct dosage, frequency, and administration technique.

Official Administration Guidelines

Procedural Conditions and Use Constraints

Proper use of the gel requires adherence to specific procedural steps. The container must be held vertically during instillation, and the tip of the container must not come into contact with the eye or any surrounding surface to maintain product sterility.

When co-administered with other topical eye treatments, the Carbomer ophthalmic gel must always be applied last. A minimum interval of at least 5 to 15 minutes must be observed between instillation of this gel and other eye preparations.

Population-Specific Use

Older Adults (over 65 years) require no dosage amendment. For Children and Adolescents (under 18 years), the standard adult dose is used, which is established by clinical experience. Contact lenses must be removed prior to application and should not be reinserted until at least 15 minutes after the gel has been instilled.

Lacrinorm: Recent Clinical Evidence

Evidence for Use in Symptomatic Dry Eye Conditions

Research has examined the use of Carbomer ophthalmic gel for people experiencing dry eye conditions, including Keratoconjunctivitis Sicca (KCS). These investigations used Randomized Controlled Trials (RCTs), where the gel was studied for its use against a non-active placebo or other existing eye preparations.

Studies explored outcomes linked to inflammatory or irritative states, monitoring patient-reported outcomes describing perceived discomfort such as ocular dryness, gritty or sandy sensations, and overall eye discomfort. Researchers also looked at objective clinical outcomes, using measurements like Tear Break-Up Time (TBUT) to assess the physical stability of the tear film and staining scores to evaluate the integrity of the eye's surface. Findings describe patterns observed in the studies regarding the evolution of these symptoms and signs over the short term. Studies report how symptoms evolved in the observed populations.

How Carbomer Gel Was Studied Against Other Preparations

Comparative studies were used in research exploring how symptoms change over time when applying Carbomer gel versus other tear substitutes, such as less viscous eye drops. The research monitored the effects of the gel formulation and used comparative studies to examine outcomes versus an inactive placebo or other eye preparations.

Research explored whether changes in patient-reported outcomes describing perceived discomfort differed between groups receiving Carbomer gel and groups receiving other eye preparations. Research describes patterns related to changes measured during the defined study periods. Certain studies also described assessments of the ocular surface in comparison to control groups. However, findings were mixed across various comparative studies, depending on the specific product used as the comparator.

Long-term Studies and Follow-up Durations

Research has primarily focused on research exploring short-term symptom changes and physical effects. The typical observation periods employed in the main clinical trials were limited, often ranging from 2 to 8 weeks, with some studies extending follow-up for a few months.

These short follow-up durations mean that long-term effects are not fully established regarding the use of Carbomer gel. Evidence is limited for outcomes tracked over extended periods. This limitation means long-term outcomes are not fully established in formal, controlled clinical trials.

Research in Specific Patient Groups

Research has focused on adult populations diagnosed with various severities of Dry Eye Syndrome. Some trials specifically enrolled patients with moderate-to-severe disease, and research has explored responses in certain subgroups, such as those with Sjögren's syndrome. This means that results apply only to the populations studied.

Data for certain groups remain insufficient. Specifically, the research base includes limited information from formal, dedicated clinical trials designed to assess the use of Carbomer gel in children and adolescents.

Areas Where Research is Still Developing

Studies have monitored the effects of the gel formulation, and this research highlights what is known—and what is still uncertain—about its use. One documented limitation is the variability in the definition and severity criteria for Dry Eye Disease across published studies.

Furthermore, research describes challenges in objective clinical assessment. The gel's viscosity appears to physically interfere with the standardization of certain objective clinical outcomes—such as staining tests. Due to these factors, evidence quality varies across studies, and comparative evidence is lacking for many contemporary artificial tear formulations. Research is ongoing to better understand these subtle factors and refine objective measurement techniques.

Common questions about Lacrinorm (FAQ)

Q: How quickly is Lacrinorm expected to start working?

The physical process by which the gel thickens the tear film begins immediately upon application to the eye's surface. Official information indicates that this immediate physical action is designed to support symptomatic relief.

Q: How long does the effect of Lacrinorm typically last?

According to the official product information, the gel formulation is designed to have a high residence time on the ocular surface. This means it provides a more prolonged moisturizing and lubricating effect compared to alternatives with lower viscosity, assisting in sustained symptomatic management.

Q: Can people with kidney problems use Lacrinorm?

Regulatory documents state that the active ingredient in Lacrinorm has negligible systemic absorption, meaning it does not substantially enter the bloodstream. Because of this, it is not associated with classic systemic drug interactions or documented impact on systemic organ function, such as the kidneys.

Q: Are there any reports about Lacrinorm causing sensitivity to light?

The official regulatory documents contain a classified list of all documented adverse reactions. Sensitivity to light, known clinically as photophobia, is not listed among the side effects reported in clinical trials or post-marketing surveillance.

Q: Are there any specific activities to avoid while using Lacrinorm?

The most common side effect is transient blurred vision, which occurs immediately after application. Regulatory labeling advises that this temporary visual effect may impact activities like driving or operating machinery. The official advisory recommends that users wait until vision is completely clear before engaging in such activities.

Q: What is the difference between Lacrinorm and an over-the-counter product for similar use?

The core difference is defined by the gel's unique formulation, specifically its high viscosity and mucoadhesive properties. The Carbomer gel is designed to create a stable, protective coating that remains on the eye's surface for a longer duration than simple, less viscous eye drops.

Q: Why do some people experience a mild tingling sensation when using Lacrinorm?

A mild tingling sensation may be a manifestation of the officially documented side effects of eye discomfort or eye irritation. These effects are classified in official documents as common, meaning they may affect up to 1 in 10 users.

Q: Does Lacrinorm have any official warnings about driving or operating machinery?

Official regulatory labeling includes a warning related to the transient blurred vision that patients may experience right after applying the gel. This temporary visual disturbance may affect the ability to drive or safely operate machinery until vision has fully cleared.

Q: Is Lacrinorm safe to use during the summer months or in hot climates?

Official instructions define specific storage requirements to maintain the product's stability and effectiveness. Official regulatory information specifies the medicine should be stored at a temperature not exceeding 25 C and protected from excessive heat and direct sunlight.

Q: Can people with high blood pressure use Lacrinorm?

The active ingredient in Lacrinorm is described in official documentation as having negligible systemic absorption. This means it is not associated with systemic drug interactions or expected impact on pre-existing systemic conditions such as high blood pressure.

Q: What is the function of the inactive ingredients listed in Lacrinorm?

Inactive ingredients, or excipients, primarily serve to create and stabilize the aqueous hydrogel base of the product. The preservative, such as benzalkonium chloride, has a non-specific antimicrobial effect to maintain the product's sterility during use.

Q: What does the term 'contraindication' mean in relation to Lacrinorm?

A contraindication is an official statement in the regulatory documents that describes a condition which makes the use of the medicine unsuitable. For Lacrinorm, the absolute contraindication is a known hypersensitivity to the active substance (carbomer) or any of its excipients.

Q: Can Lacrinorm be used by people who have diabetes?

According to official information, the active ingredient has negligible systemic absorption, meaning it does not significantly enter the body's systems. Because of this localized effect, Lacrinorm is not associated with impacts on pre-existing systemic conditions like diabetes.

Q: Is Lacrinorm known to cause dryness in other parts of the body?

The official safety profile indicates that documented adverse effects are primarily local to the eye. Negligible systemic absorption is anticipated, meaning systemic effects—such as dryness in other parts of the body—are not documented in regulatory information.

Q: Does Lacrinorm require a prescription in most places?

The legal classification of the product is noted in official regulatory documentation. This designation indicates whether the medicine is classified as a Prescription-only medicine or is authorized for Over-the-counter status.

Q: What happens if I forget to use Lacrinorm one day?

Official instructions generally provide guidance for managing missed applications. This guidance typically states that the forgotten dose should be skipped, and the individual should then continue the usual routine at the next scheduled application time.

Q: Are there different strengths or versions of Lacrinorm available?

Official regulatory documents describe the approved composition of Lacrinorm as a single Ophthalmic Gel formulation containing Carbomer. No other strengths, forms, or versions of the product are included in the official labeling.

Q: Is it normal for the product to feel slightly thicker or runnier sometimes?

The product is manufactured to meet specific, defined viscosity standards. The official documentation covers the acceptable range for the product's physical consistency and may contain instructions for usage or storage that address minor perceived variations.

Q: Is the list of side effects in the official documents comprehensive?

The list of adverse reactions provided in the official documentation represents effects observed in both clinical trials and during post-marketing surveillance. Regulatory agencies categorize these effects by their frequency of occurrence, ensuring transparency regarding what has been observed and reported.

Q: Why is Lacrinorm packaged in a specific type of container?

The container design is closely linked to the official instructions for use, which emphasize preventing the tip from touching the eye or other surfaces. This constraint is a requirement intended to maintain the product's sterility and ensure proper administration.

Q: Is it possible to use Lacrinorm too often?

Official regulatory documents define the maximum recommended frequency for use to be between three and four times daily, or as required for symptom management. No information is provided that defines a risk of using the product more often than this recommended schedule.

Q: What information is provided about potential over-exposure to Lacrinorm?

Official prescribing information covers the scenario of accidental over-exposure or overdose. Due to the gel's method of application and the negligible systemic absorption anticipated, it is stated that over-exposure is unlikely to cause systemic effects of concern.

How to Store and Dispose of Lacrinorm

Lacrinorm (Carbomer ophthalmic gel) must be stored in specific environmental conditions to maintain its effectiveness and sterility. The product should be stored at a temperature not exceeding 25 C and must be protected from excessive heat, moisture, and direct sunlight.

Stability and Handling

To prevent contamination, the container must be closed tightly after each use. Once opened, the product has a limited shelf-life and must be discarded after 30 days (4 weeks). Always store the medicine out of the sight and reach of children.

Disposal

For disposal, do not throw the medicine away with household waste or wastewater. Patients should consult their pharmacist for the appropriate method to discard unused or expired Lacrinorm.